TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Raised CA125 – what we actually know
Key Statistics
- <35 IU/ml — Normal CA125 (most assays)
- >250 IU/ml — Triggers cancer-centre referral
- 70%+ — Ovarian cancer presents stage III/IV
Don't-miss facts
-
Normal CA125 <35 IU/ml; >250 IU/ml in an ovarian cyst → refer to cancer centre
-
CA125 arises from mesothelial cell stress (mechanical/inflammatory) – not directly from the tumour
-
Sensitivity only 75–90% in advanced disease; 50% of stage I cancers have a normal level – unsuitable as a stand-alone screening test
-
Falls by half within 10 days post-resection; normalises by 1.5 months (complete remission) vs 4 months (partial remission); 40% with normal CA125 still have disease at second-look surgery
-
BGCS: routine follow-up CA125 testing is not mandatory, no proven survival benefit
-
RCOG: not needed for simple premenopausal cysts (use IOTA M/B rules); essential if postmenopausal with cyst >1 cm
-
Raised in menstruation, pregnancy (1st trimester ↑, pre-eclampsia), endometriosis (stage II+, may reach hundreds U/ml), smoking, breast cancer, HRT, cirrhosis, cardiac disease
-
HE4/ROMA more specific adjuncts; ROCA tracks trend but costly, no mortality benefit shown
Cut-offs at a glance
<35 IU/ml: normal >35 IU/ml (symptomatic): image (TVUSS) >250 IU/ml + cyst: refer cancer centre
Postmenopausal cyst >1cm: CA125 essential
Abbreviation Key
- CA125 — carbohydrate antigen 125
- CA19-9 — carbohydrate antigen 19-9
- MUC16 — mucin 16 (gene encoding CA125, chromosome 19)
- CEA — carcinoembryonic antigen
- TVUSS — transvaginal ultrasound scanning
- HE4 — human epididymis protein 4 (WFDC2)
- RMI — risk of malignancy index
- ROMA — risk of ovarian malignancy algorithm
- BGCS — British Gynaecological Cancer Society
- ROCA — risk of ovarian cancer algorithm
- NICE — National Institute for Health and Care Excellence
- HRT — hormone replacement therapy
- RCOG — Royal College of Obstetricians and Gynaecologists
- CHF — chronic heart failure
- IOTA — International Ovarian Tumor Analysis
- CT — computed tomography
- MDT — multidisciplinary team
Source: Howe C, et al. Raised CA125 – what we actually know. The Obstetrician & Gynaecologist 2021;23:21–27. doi:10.1111/tog.12704
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).